|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
16.70(B) |
Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
52
Week Range: |
$76.22 - $99 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 811 |
Guru Rank Value : 0.9 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
159,588 |
251,929 |
319,053 |
656,089 |
Total Sell Value |
$13,270,852 |
$21,508,551 |
$27,661,182 |
$61,420,002 |
Total People Sold |
5 |
6 |
7 |
7 |
Total Sell Transactions |
10 |
19 |
27 |
56 |
End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bienaime Jean Jacques |
Chief Executive Officer |
|
2023-03-10 |
4 |
OE |
$67.81 |
$1,017,150 |
D/D |
15,000 |
502,856 |
|
- |
|
Mueller Brian |
EVP, Chief Financial Officer |
|
2023-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
24,890 |
52,636 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2023-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
167,532 |
487,856 |
|
- |
|
Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
|
2023-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
38,769 |
79,857 |
|
- |
|
Fuchs Henry J |
President, Worldwide R&D |
|
2023-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
68,052 |
212,146 |
|
- |
|
Davis George Eric |
EVP, Chief Legal Officer |
|
2023-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
37,724 |
94,449 |
|
- |
|
Davis George Eric |
EVP, Chief Legal Officer |
|
2023-02-24 |
4 |
OE |
$67.81 |
$99,952 |
D/D |
1,474 |
56,725 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2023-02-13 |
4 |
AS |
$109.15 |
$654,900 |
D/D |
(6,000) |
320,324 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2023-02-13 |
4 |
OE |
$67.81 |
$406,860 |
D/D |
6,000 |
326,324 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2023-02-10 |
4 |
AS |
$110.11 |
$1,651,650 |
D/D |
(15,000) |
320,324 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2023-02-10 |
4 |
OE |
$67.81 |
$1,017,150 |
D/D |
15,000 |
335,324 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2023-02-07 |
4 |
GA |
$0.00 |
$0 |
I/I |
200 |
100 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2023-02-07 |
4 |
GD |
$0.00 |
$0 |
I/I |
200 |
247,333 |
|
- |
|
Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
|
2023-01-25 |
4 |
AS |
$115.65 |
$5,669,134 |
D/D |
(49,000) |
41,088 |
|
- |
|
Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
|
2023-01-25 |
4 |
OE |
$67.81 |
$3,322,690 |
D/D |
49,000 |
90,088 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2023-01-17 |
4 |
AS |
$111.55 |
$1,115,500 |
D/D |
(10,000) |
320,424 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2023-01-17 |
4 |
OE |
$67.81 |
$678,100 |
D/D |
10,000 |
330,424 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2023-01-13 |
4 |
AS |
$112.25 |
$1,122,500 |
D/D |
(10,000) |
320,424 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2023-01-13 |
4 |
OE |
$67.81 |
$678,100 |
D/D |
10,000 |
330,424 |
|
- |
|
Mueller Brian |
EVP, Chief Financial Officer |
|
2023-01-13 |
4 |
AS |
$114.50 |
$286,250 |
D/D |
(2,500) |
27,746 |
|
- |
|
Mueller Brian |
EVP, Chief Financial Officer |
|
2023-01-13 |
4 |
OE |
$63.10 |
$157,750 |
D/D |
2,500 |
30,246 |
|
- |
|
Mueller Brian |
EVP, Chief Financial Officer |
|
2022-12-13 |
4 |
AS |
$107.50 |
$268,750 |
D/D |
(2,500) |
27,746 |
|
- |
|
Mueller Brian |
EVP, Chief Financial Officer |
|
2022-12-13 |
4 |
OE |
$63.10 |
$157,750 |
D/D |
2,500 |
30,246 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2022-12-13 |
4 |
S |
$106.89 |
$106,890 |
D/D |
(1,000) |
320,424 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2022-12-02 |
4 |
S |
$103.97 |
$155,967 |
D/D |
(1,500) |
321,424 |
|
- |
|
1285 Records found
|
|
Page 7 of 52 |
|
|